A database of FDA approved therapeutic peptides and proteins
| ID | ThPPID | Name | Peptide Sequence | Length | Functional Classification | Disease | Brand | Company | Physical Appearance | Route of Administartion | Category | Target |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1415 | Th1069 | Pegvisomant | FPTIPLSRLFDNAMLRAHRL Full view | 191 | IIa | Hormonal | SOMAVERT | Pfizer | Sterile, white lyophilized powder | Subcutaneous Injection | Hormone Replacement Agents | B-lymphocyte antigen CD20,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c |
| 1419 | Th1070 | Botulinum Toxin Type A | MPFVNKQFNYKDPVNGVDIA Full view | 1296 | Ic | Neurological Disorder | BOTOX | Allergan | Sterile, vacuum-dried purified botulinum toxin type A, produced from fermentation of Hall strainClostridium botulinum type A | Intramuscular, intradetrusor and intradermal use | Neuromuscular Blocking Agents, Anti-Wrinkle Agents and Antidystonic Agents | Growth hormone receptor |
| 1420 | Th1070 | Botulinum Toxin Type A | MPFVNKQFNYKDPVNGVDIA Full view | 1296 | Ic | Neurological Disorder | Dysport | Ipsen Pharmaceuticals | Sterile vial for reconstitution | Intramuscular Injection | Neuromuscular Blocking Agents, Anti-Wrinkle Agents and Antidystonic Agents | Growth hormone receptor |
| 1421 | Th1070 | Botulinum Toxin Type A | MPFVNKQFNYKDPVNGVDIA Full view | 1296 | Ic | Neurological Disorder | Xeomin | MERZ AESTHETICS | Sterile white to off-white lyophilized powder after reconstitution with preservative-free 0.9% Saline for Injection. | Intramuscular Injection | Neuromuscular Blocking Agents, Anti-Wrinkle Agents and Antidystonic Agents | Growth hormone receptor |
| 1434 | Th1074 | Alglucerase | ARPCIPKSFGYSSVVCVCNA Full view | 497 | Ia | Metabolic | Ceredase | Genzyme Corporation | Clear sterile non-pyrogenic solution of alglucerase in a citrate buffered solution | Intravenous injection | Enzyme Replacement Agents | Plasminogen,Proteinase-activated receptor 1 |
| 1435 | Th1075 | Capromab | N.A. Full view | 0 | IV | Cancer | ProstaScint | Jazz Pharmaceuticals, Inc. | Sterile, pyrogen-free, clear, colorless solution that may contain some translucent particles. | Intravenous injection | Indicators, Reagents and Diagnostic Agents | CAMPATH-1 antigen,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c |
| 1447 | Th1080 | Choriogonadotropin Alfa | Alpha chain: APDVQDC Full view | 237 | Ib | Hormonal | Choriogonadotropin alfa | Emd serono inc, Ferring pharmaceuticals inc, App pharmaceuticals llc, Bel mar laboratories inc, Bris | N.A. | N.A. | Fertility Agents and Gonadotropins | Integrin alpha-L, Low affinity immunoglobulin gamma Fc region receptor III-B, Complement C1r subcomponent, Complement C1q subcomponent subunit A, Complement C1q subcomponent subunit B, Complement C1q subcomponent subunit C, Low affinity immunoglobulin gamma Fc region receptor III-A, High affinity immunoglobulin gamma Fc receptor I, Low affinity immunoglobulin gamma Fc region receptor II-a, Low affinity immunoglobulin gamma Fc region receptor II-b, Low affinity immunoglobulin gamma Fc region receptor II-c |
| 1451 | Th1082 | Filgrastim | MTPLGPASSLPQSFLLKCLE Full view | 175 | Ib | Immunological | N.A. | N.A. | N.A. | N.A. | Immunosuppressive Agents, Antineutropenic Agents and Hematopoietic Agents | Lutropin-choriogonadotropic hormone receptor,Follicle-stimulating hormone receptor |
| 1454 | Th1084 | Becaplermin | SLGSLTIAEPAMIAECKTRT Full view | 109 | Ib | Cardiac | REGRANEX | OMJ Pharmaceuticals, Inc. San German, Puerto Rico | Gel: 0.01 %; clear, colorless to straw-colored gel | External use only | Angiogenesis Inducing Agents | T-cell surface glycoprotein CD1a,Major histocompatibility complex class I-related gene protein,Integrin alpha-L,T-lymphocyte activation antigen CD86,Low affinity immunoglobulin gamma Fc region receptor II-b,T-cell surface glycoprotein CD4,Integrin beta-1,Integrin alpha-V,Integrin beta-3 |
| 1456 | Th1086 | Interferon Alfa-2B, Recombinant | CDLPQTHSLGSRRTLMLLAQ Full view | 165 | Ib | Immunological | INTRON® A | Merck | Powder or solution | Intramuscular, Subcutaneous, Intralesional, or Intravenous injection | Immunosuppressive Agents | Granulocyte colony-stimulating factor receptor,Neutrophil elastase, Coagulation factor X,Coagulation factor XI,Coagulation factor VII,Coagulation factor VIII,Prothrombin,Prolow-density lipoprotein receptor-related protein 1,Vitamin K-dependent gamma-carboxylase, Platelet-derived growth factor receptor beta,Platelet-derived growth factor receptor alpha,Alpha-2-macroglobulin |
| 1460 | Th1087 | Oxytocin | CYIQNCPLG Full view | 9 | Ib | Hormonal | Pitocin | JHP Pharmaceuticals | Sterile, clear, colorless aqueous solution of synthetic oxytocin | Intravenous infusion | Oxytocics, Anti-tocolytic Agents and Labor Induction Agents | Interferon alpha/beta receptor 2,Interferon alpha/beta receptor 1, Globotriaosylceramide |
| 1462 | Th1088 | Enfuvirtide | YTSLIHSLIEESQNQQEKNE Full view | 36 | IIa | Infectious | `FUZEON | Trimeris, Roche | White to off-white, sterile, lyophilized powder. | Subcutaneous injection | HIV Fusion Inhibitors | Oxytocin receptor,Oxytocin-neurophysin 1, Envelope glycoprotein |
| 1466 | Th1090 | Daclizumab | QVQLVQSGAEVKKPGSSVKV Full view | 674 | IIa | Immunologicals | Zenapax | Roche | Clear, sterile, colorless concentrate for further dilution and intravenous administration | Intravenous injection | Immunosuppressive Agents | Fusion glycoprotein F0,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c |
| 1468 | Th1091 | Bevacizumab | DIQMTQSPSSLSASVGDRVT Full view | 214 | IIa | Cardiac | Avastin | Genentech | Slightly opalescent, colorless to pale brown, sterile, pH 6.2 solution for intravenous infusion | Intravenous infusion | Angiogenesis Inhibitors | Interleukin-2 receptor subunit alpha,Interleukin-2 receptor subunit beta,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c |
| 1470 | Th1092 | Arcitumomab | Heavy chain 1EVKLVES Full view | 1310 | IIb | Cancer | CEA-Scan | N.A. | N.A. | N.A. | Diagnostic Agents | Vascular endothelial growth factor A,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c, Carcinoembryonic antigen-related cell adhesion molecule 1 |
| 1474 | Th1094 | Panitumumab | N.A. Full view | 0 | IIa | Cancer | Vectibix | Amgen Inc | Sterile, colorless, pH 5.6 to 6.0 liquid for intravenous (IV) infusion, which may contain a small amount of visible translucent-to-white, amorphous, proteinaceous, panitumumab particulates | N.A. | N.A. | Epidermal growth factor receptor |
| 1477 | Th1097 | Alglucosidase Alfa | AHPGRPRAVPTQCDVPPNSR Full view | 882 | Ic | Metabolic | LUMIZYME | Genzyme | Sterile, nonpyrogenic, white to off-white, lyophilized cake or powder for reconstitution with 10.3 Ml Sterile Water for Injection, USP | Intravenous infusion | Enzyme Replacement Agents | Cation-dependent mannose-6-phosphate receptor,Glycogen |
| 1478 | Th1098 | Exenatide | HGEGTFTSDLSKQMEEEAVR Full view | 39 | Ib | Hormonal/Metabolic | BYETTA | N.A. | N.A. | N.A. | Hypoglycemic Agents | Glucagon-like peptide 1 receptor |
| 1479 | Th1098 | Exenatide | HGEGTFTSDLSKQMEEEAVR Full view | 39 | Ib | Hormonal/Metabolic | BYDUREON | Amylin Pharmaceuticals | White to off-white powder that is available in a dosage strength of 2 mg exenatide per vial or per pen | N.A. | Hypoglycemic Agents | Glucagon-like peptide 1 receptor |
| 1480 | Th1099 | Mecasermin | GPETLCGAELVDALQFVCGD Full view | 70 | Ib | Hormonal | N.A. | N.A. | N.A. | N.A. | N.A. | Insulin-like growth factor 1 receptor,Insulin-like growth factor-binding protein 3,Insulin receptor,Cation-independent mannose-6-phosphate receptor |
| 1482 | Th1100 | Pramlintide | KCNTATCATQRLANFLVHSS Full view | 37 | Ia | Hormonal/Metabolic | Symlin | Amylin Pharmaceuticals (now a wholly owned subsidiary of AstraZeneca) | Clear, isotonic, sterile solution | Subcutaneous injection | N.A. | Calcitonin receptor,Receptor activity-modifying protein 1,Receptor activity-modifying protein 2,Receptor activity-modifying protein 3 |
| 1500 | Th1103 | Cosyntropin | ACTH(1-24): SYSM Full view | 24 | IV | Hormonal | Cortrosyn | Amphastar Pharmaceuticals | N.A. | Intravenous injection, Intravenous infusion, Intramuscular injection | Hormones and Diagnostic Agents | Adrenocorticotropic hormone receptor |
| 1502 | Th1105 | Insulin Aspart | A chain: GIVEQCCTSIC Full view | 51 | Ia | Hormonal/Metabolic | NovoLog | Novo Nordisk | Sterile, aqueous, clear, and colorless solution | Subcutaneous injection, Intravenous injection | Hypoglycemic Agents and Antidiabetic Agents | Insulin receptor |
| 1503 | Th1105 | Insulin Aspart | A chain: GIVEQCCTSIC Full view | 51 | Ia | Hormonal/Metabolic | NovoLog Mix 50/50 | Novo Nordisk | Uniform, white, sterile suspension that contains insulin aspart | Subcutaneous injection | Hypoglycemic Agents and Antidiabetic Agents | Insulin receptor |
| 1504 | Th1105 | Insulin Aspart | A chain: GIVEQCCTSIC Full view | 51 | Ia | Hormonal/Metabolic | NovoLog Mix 70/30 | Novo Nordisk | Uniform, white, sterile suspension that contains insulin aspart 100 Units/mL. | Subcutaneous injection | Hypoglycemic Agents and Antidiabetic Agents | Insulin receptor |
| 1511 | Th1106 | Insulin Detemir | A chain: GIVEQCCTSIC Full view | 51 | Ia | Hormonal/Metabolic | LEVEMIR | Novo Nordisk | Clear, colorless, aqueous, neutral sterile solution | Subcutaneous injection | Antidiabetic Agents | Insulin receptor |
| 1520 | Th1107 | Insulin Glulisine | A chain: GIVEQCCTSIC Full view | 51 | Ib | Hormonal/Metabolic | APIDRA | sanofi-aventis | Sterile, aqueous, clear, and colorless solution | N.A. | Antidiabetic Agents | Insulin receptor |
| 1532 | Th1111 | Defibrotide | N.A. Full view | 0 | Ib | Immunological | Noravid | sanofi-aventis | N.A. | N.A. | Antithrombins | Adenosine receptor A1,Adenosine receptor A2a,Adenosine receptor A2b |
| 1535 | Th1114 | Preotact | Parathyroid hormone: Full view | 84 | Ib | Osteological | Preotact | Nycomed | N.A. | Subcutaneous injection | N.A. | Parathyroid hormone/parathyroid hormone-related peptide receptor,Parathyroid hormone 2 receptor |
| 1550 | Th1119 | Tocilizumab | N.A. Full view | 0 | IIa | Immunological | ACTEMRA | Genentech | Sterile, preservative-free solution, colorless to pale yellow liquid, with a pH of about 6.5 | Intravenous infusion, Subcutaneous injection | N.A. | Interleukin-6 receptor subunit alpha |
| 1556 | Th1120 | Teriparatide | Parathyroid hormone Full view | 34 | Ib | Osteological | Forteo | Eli Lilly and Company | Sterile, colorless, clear, isotonic solution | Subcutaneous injection | Bone Density Conservation Agents | Parathyroid hormone/parathyroid hormone-related peptide receptor |
| 1560 | Th1121 | Pertuzumab | light chain DIQMTQSP Full view | 664 | IIIc | Cancer | Perjeta | Genentech | Sterile, clear to slightly opalescent, colorless to pale brown liquid | Intravenous infusion | Monoclonal antibodies | Receptor tyrosine-protein kinase erbB-2 |
| 1562 | Th1122 | Rilonacept | rilonacept|Homo sapi Full view | 880 | IIa | Immunological | Arcalyst | Regeneron Pharmaceuticals | Sterile, white to off-white, lyophilized powder | Subcutaneous injection | Immunosuppressive Agents | Interleukin-1 beta,Interleukin-1 alpha,Interleukin-1 receptor antagonist protein |
| 1576 | Th1124 | Liraglutide | HAEGTFTSDVSSYLEGQAAK Full view | 33 | Ib | Hormonal | Saxenda | Novo Nordisk | Clear, colorless solution | Subcutaneous injection | N.A. | Glucagon-like peptide 1 receptor |
| 1577 | Th1124 | Liraglutide | HAEGTFTSDVSSYLEGQAAK Full view | 33 | Ib | Hormonal | Victoza | Novo Nordisk | Clear, colorless solution. | Subcutaneous injection | N.A. | Glucagon-like peptide 1 receptor |
| 1600 | Th1127 | Buserelin | N.A. Full view | 0 | IIIc | Cancer/Hormonal | Suprecur (Nasal Spray Solution) | Sanofi-Aventis | 150 micrograms Nasal Spray Solution | Nasal spray | N.A. | Lutropin-choriogonadotropic hormone receptor,Gonadotropin-releasing hormone receptor |
| 1601 | Th1127 | Buserelin | pGlu-His-Trp-Ser-Tyr Full view | 9 | IIIc | Cancer/Hormonal | Suprecur (injection) | Sanofi-Aventis | 1mg/ml Injection | Subcutaneous injection | N.A. | Lutropin-choriogonadotropic hormone receptor,Gonadotropin-releasing hormone receptor |
| 1603 | Th1129 | Tesamorelin | YADAIFTNSYRKVLGQLSAR Full view | 44 | Ib | Hormonal | Egrifta | Theratechnologies | Sterile, white to off-white, preservative-free lyophilized powder | Subcutaneous injection | N.A. | Growth hormone-releasing hormone receptor |
| 1604 | Th1130 | Brentuximab Vedotin | Heavy chain:QIQLQQSG Full view | 664 | IIb | Cancer | Adcetris | Seattle Genetics | Sterile, white to off-white, preservative-free lyophilized cake or powder in single-use vials. | Intravenous infusion | N.A. | Tumor necrosis factor receptor superfamily member 8 |
| 1624 | Th1137 | Teduglutide | HGDGSFSDEMNTILDNLAAR Full view | 33 | Ia | Malabsorption disorder | Gattex | NPS Pharmaceuticals, Inc | Clear, colorless to light-straw–colored liquid. | Subcutaneous injection | N.A. | Glucagon-like peptide 2 receptor |
| 1634 | Th1140 | Insulin, Isophane Or Nph Insulin (Neutral Protamine Hagedorn) | A chain: GIVEQCCTSIC Full view | 51 | Ia | Hormonal/Metabolic | Novolin N | Novo Nordisk | Novolin N InnoLet (nph, human insulin isophane suspension 3 ml disposable prefilled syringe) | Subcutaneous injection | Hypoglycemic Agents and Antidiabetic Agents | Insulin receptor |
| 1635 | Th1141 | Epoetin Zeta | APPRLICDSRVLERYLLEAK Full view | 166 | Ib | Cancer | Retacrit | Norbitec | solution for injection | N.A. | N.A. | Erythropoietin receptor |
| 1655 | Th1151 | Somatotropin Recombinant | FPTIPLSRLFDNAMLRAHRL Full view | 192 | Ib | Hormonal/Metabolic | NutropinAQ | Genentech Inc. | Sterile, white lyophilized powder intended for subcutaneous administration after reconstitution with Bacteriostatic Water | Subcutaneous administration | Hormone Replacement Agents | Growth hormone receptor, Prolactin receptor |
| 1656 | Th1151 | Somatotropin Recombinant | FPTIPLSRLFDNAMLRAHRL Full view | 192 | Ib | Hormonal/Metabolic | BioTropin | Bio-Technology General (Israel) Ltd. | Sterile, white, lyophilized powder | Subcutaneous administration | Hormone Replacement Agents | Growth hormone receptor, Prolactin receptor |
| 1657 | Th1151 | Somatotropin Recombinant | FPTIPLSRLFDNAMLRAHRL Full view | 192 | Ib | Hormonal/Metabolic | Protropin | Genentech Inc. | Sterile, white, lyophilized powder | Intramuscular or subcutaneous administration | Hormone Replacement Agents | Growth hormone receptor, Prolactin receptor |
| 1659 | Th1152 | Drotrecogin alfa | Heavy Chain: LIDGKMT Full view | 402 | Ib | Infectious | Xigris | Eli Lilly and Company | Sterile, lyophilized, white to off-white powder | Intravenous Infusion | Antisepsis | Coagulation factor VIII, V, Plasminogen activator inhibitor 1, Thrombomodulin, Vitamin K-dependent protein S, Ceruloplasmin, Prothrombin, Platelet factor 4, Plasma serine protease inhibitor, Serpin B6, Vitamin K-dependent gamma-carboxylase, Endothelial protein C receptor |
| 1661 | Th1153 | Alefacept | Heavy Chain: CFSQQIY Full view | 705 | IIa | Immunological | Amevive | Astellas Pharma Inc. | Sterile, white-to-off-white, preservative-free, lyophilized powder | Intramuscular Injection | Dermatologic and Immunosupressive agents | T-cell surface antigen CD2, Complement C1r subcomponent, Complement C1q subcomponent subunit A, B, C, Low affinity immunoglobulin gamma Fc region receptor III-A,III-B, II-a, II-b, II-c |
| 1662 | Th1154 | OspA lipoprotein | MKKYLLGIGLILALIACKQN Full view | 272 | IIIa | Infectious | Lymerix | SmithKline Beecham | Sterile suspension | Intramuscular Injection | Vaccines | Toll-like receptor 2 |
| 1663 | Th1155 | Urokinase | KPSSPPEELKFQCGQKTLRP Full view | 276 | Ib | Haemetological | Kinlytic | N.A. | Sterile lyophilized white powder | Intravenous infusion | N.A. | Plasminogen,Urokinase plasminogen activator surface receptor, Urokinase-type plasminogen activator, Tissue-type plasminogen activator, Plasminogen activator inhibitor 1, 2, Plasma serine protease inhibitor, Low-density lipoprotein receptor-related protein 2, Suppressor of tumorigenicity 14 protein, Nidogen-1 |
| 1664 | Th1156 | Abarelix | N.A. Full view | 0 | IIIc | Hormonal | Plenaxis | Speciality european pharma | White to off-white sterile dry powder | Intramuscular Injection | Anti-Testosterone Agents | Gonadotropin-releasing hormone receptor |